Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase II drugs for Metastatic Adenocarcinoma of The Pancreas have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Defactinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Defactinib hydrochloride overview
Defactinib hydrochloride (VS-6063) is under development for the treatment of pancreatic ductal adenocarcinoma as adjuvant therapy, metastatic uveal melanoma, KRAS-mutated NSCLC, colorectal cancer, malignant pleural mesothelioma, pancreatic ductal adenocarcinoma, metastatic adenocarcinoma of the pancreas, endometrial cancer, prostate cancer, epithelial ovarian cancer, fallopian tube cancer, low-grade serous ovarian cancer, peritoneal cancer, triple negative breast cancer and pancreatic cancer. The drug candidate is administered by oral route. VS-6063 is a selective inhibitor of the FAK family kinases focal adhesion kinase (FAK) and protein tyrosine kinase 2 Beta (PTK-2B). It was also under development for malignant pleural mesothelioma in EU and solid tumors (non-hematologic malignancy).
Verastem is a biopharmaceutical company. It carries out the discovery, development, and commercialization of novel small molecule drugs to treat cancer. The company’s most advanced product candidates include VS-6766, defactinib (VS-6063). Verastem products VS-6766 and defactinib (VS-6063), are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. The pipeline products focused on RAF/MEK inhibition and FAK inhibition. Its service include investigator sponsored trial (IST)program. The company operates in Germany and the US. Verastem is headquartered in Needham, Massachusetts, the US.
For a complete picture of Defactinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.